TABLE 1.
Parameters | Data |
---|---|
Male, n (%) | 20 (69.0%) |
Mean age, years | 58.1 ± 10.6 |
Lesion types | |
Right lobe | 14 (48.3%) |
Left lobe | 1 (3.4%) |
Bi-lobar | 14 (48.3%) |
Symptom duration, months | 1.0 (0.4, 10.5) |
Recurrence after surgery | 5 (17.2%) |
Systemic treatments | 21 (72.4%) |
Targeted therapy | 9 (31.0%) |
Immunotherapy | 2 (6.9%) |
Targeted and immunotherapy | 10 (34.5%) |
Hepatitis B virus infection | 14 (48.3%) |
BCLC stage B/C | 8 (27.6%)/21 (72.4%) |
Child–Pugh class A/B | 20 (69.0%)/9 (31.0%) |
Multinodular/bulky tumor/diffuse | 5 (17.2%)/11 (37.9%)/13 (44.8%) |
Portal vein trunk or IVC invasion | 5 (17.2%) |
Portal vein or hepatic vein branch invasion | 7 (24.1%) |
Extrahepatic sites | 13 (44.8%) |
Lung | 2 (6.9%) |
Lymph node | 10 (34.5%) |
Bone | 2 (6.9%) |
Spleen | 1 (3.4%) |
Tumor diameter, mm | 91.6 ± 41.2 |
a-Fetoprotein level | 24 (82.8%) |
Normal | 7 (24.1%) |
<400 ng/ml | 4 (13.8%) |
400–10,000 ng/ml | 8 (27.6%) |
>10,000 ng/ml | 5 (17.2%) |
IVC = Inferior vena cava.